^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MP0250

    i
    Other names: MP0250, MP0250 DARPin drug, MP 0250, MP0250 designed repeat protein
    Associations

    News

    Trials
    Company:
    Molecular Partners
    Drug class:
    VEGF-A inhibitor, Hepatocyte growth factor inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. (PubMed, J Clin Oncol)
    MP0250 is a first-in-class DARPin drug candidate with suitable tolerability and appropriate pharmacokinetic properties for further development in combination with other anticancer therapies.
    Clinical • P1 data • Journal
    |
    VEGFA (Vascular endothelial growth factor A)
    |
    MP0250
    almost4years
    MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC (clinicaltrials.gov)
    P1b/2, N=8, Terminated, Molecular Partners AG | N=40 --> 8 | Trial completion date: Jul 2021 --> Apr 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2021 --> Aug 2019; Sponsor's decision
    Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • MP0250
    over4years
    The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs (ASH 2019)
    Analysis of the preliminary efficacy results showed an encouraging ORR of 40%. Recruitment to this Phase 2 study is ongoing.
    Clinical • P2 data
    |
    HGF (Hepatocyte growth factor)
    |
    bortezomib • MP0250